PET imaging aids researchers in search for anti-nicotine vaccine, but shows there is still a lot of work to do.
[[{"type":"media","view_mode":"media_crop","fid":"13937","attributes":{"alt":"PET shows nicotine in smokers' brains","class":"media-image media-image-right","id":"media_crop_1274890203757","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"657","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"margin: 5px; float: right; height: 141px; width: 100px;","title":"","typeof":"foaf:Image"}}]]PET brain images show that researchers are not any closer to developing an effective anti-nicotine vaccine, according to a presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2013 annual meeting.
Scientists have been working to develop an anti-nicotine vaccine to inhibit nicotine action, eliminating the pleasure-producing chemical response in the brain. However, the latest attempt is showing mixed success, as evidenced by PET brain scans on smokers who have received the experimental vaccine.
The anti-nicotine immunization introduces an antigen that induces production of antibodies that bind circulating nicotine and prevent it from crossing the blood-brain barrier to produce rewarding effects in smokers. To determine if the vaccine was effective, researchers recruited smokers who smoked more than 10 cigarettes per day. The researchers scanned each subject’s brain twice, as they smoked. The first scan was performed before the smokers were given the experimental vaccine, and the second was done two weeks after they received the last dose. Each scan was done with the patient taking a single puff of a cigarette containing S-nicotine labeled with radioactive C-11.
“Ideally, we want [the vaccine] to decrease amount of nicotine that reaches the brain, but when we compared the immune response across subjects, their antibodies appeared to vary in nicotine-binding properties,” Alexey G. Mukhin, MD, PhD, said in a release. Mukhin is a professor or psychiatry and behavioral science at Duke University.
The results showed that 10 subjects with the highest vaccine-induced serum capacity to bind nicotine had high-affinity antibodies and experienced a slight but statistically significant decrease in accumulation of nicotine in the brain. Another 10 subject who had intermediate serum nicotine binding capacity and low affinity of antibodies showed the opposite response. They had an increase in nicotine accumulation.
“These results are important because they tell us that we should care about not only the amount of antibody, but the quality of the antibody,” explained Mukhin. “We don’t want to have low-affinity antibodies because that can negate the anti-nicotine effects of the vaccination.”
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.